Healthy Stool Volunteer Donors for Fecal Microbiota Transplantation Trials

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-49
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Currently, ANSM recommendations govern FMT (Fecal Microbiota Transplantation) in clinical trials. The collection and validation of these stool donations as part of the trials is complex and not very efficient. It therefore seems essential to identify the limiting factors and the characteristics of Healthy Volunteer Donors to optimize the number of valid stool donations.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age ≥ 18 years and < 50 years

17 kg/m² < body mass index < 30 kg/m²

Regular bowel movement defined as at least 1 stool every other day and maximum 2 stools per day

Subject with health insurance (AME excepted)

Disqualifiers

Residence of more than 2 years in the intertropics zone within the previous 5 years

Hospitalization abroad for more than 24 hours in the last 12 months (including a member of the healthy volunteers donor's entourage)

Risk factors for Creutzfeldt-Jakob disease (history: treatment with extractive growth hormone, a family case of transmissible spongiform subacute encephalopathy, surgery with opening of the dura or neurosurgery or invasive brain exploration before 1 January 1995, stay in United Kingdom for a duration greater than 1 year cumulatively between 1980 and 1996 or the presence of neurological or neuropsychiatric scalable recent clinical signs)

Previous history of typhoid fever, tuberculosis and malaria

Trial design

Design model

Single group

Treatments tested in this trial

  • Stools donation

    Other intervention

    Healthy volunteer donors included in the selection process to donate stool for the preparation of a TMF as part of research projects. Donors will be followed from their selection until 6 months after their last valid stool donation.

Treatment groups

400 Participants
are divided into 1 treatment group
Group A: Healthy volunteers for stool donationExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Proportion of HVD included who made at least 1 valid stool donation in the 12 months following their inclusion

A valid stool donation is a donation that complies with all the clinical and biological recommendations of the ANSM (Defining the rules of good practice relating to the collection, control, storage, traceability and transport of human stool samples as provided for in Article L. 513-11-2 of the Public Health Code. Decision of 7 April 2025.") Define among the Healthy Volunteer Donors-TMFs (HVD ) included, the number of (HVD ) having made at least 1 valid stool donation.

Time frame
12 months

Secondary outcomes

1

Proportion of "good donors": included donors having made at least 5 valid stool donations in the 12 months following their inclusion.

A valid stool donation is a donation that complies with all the clinical and biological recommendations of the ANSM Define among HVD included, "good donors" having made at least 5 valid stool donations

Time frame
12 months
2

Description of the clinical characteristics of HVD performing stool donation

Description of clinical characteristics (average age, average BMI) of donors who made at least 1 valid stool donation within 12 months following their inclusion and comparison with those of donors who did not not having made valid donations.

Time frame
12 months
3

Description of the lifestyle habits of HVD performing stool donation

Description of the lifestyle habits (lifestyle : profession, eating habits) of donors who made at least 1 valid stool donation within 12 months following their inclusion and comparison with those of donors who did not not having made valid donations.

Time frame
12 months
4

Reasons for non-eligibility during the inclusion visit or during the phone screening

Description of the reasons for non-eligibility during the inclusion visit or during the phone screening (non-inclusion criteria, availability, tolerance/acceptance of blood and nasopharyngeal samples, geographical distance, compensation amount, etc.) in order to evaluate the factors limiting the eligibility of HVD

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assistance Publique - Hôpitaux de Paris

Lead sponsor

CRB-SAT BARM APHP.SU

Collaborator

CRSA UMRS 938

Collaborator